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Introduction
The human immunodeficiency virus (HIV) and tuberculosis co-
infection pandemic, coupled with malnutrition, referred to as 
“triple trouble”,1 have become a serious health problem in South 
Africa. Malnutrition is common in HIV-, acquired immune deficiency 
syndrome (AIDS)- and tuberculosis-infected individuals because 
of physiological, socio-economic and psychosocial factors that 
accompany the infection. A reduction in food intake is the most 
important contributing factor in disease-related malnutrition,2  
and weakens the immune system, thereby increasing the risk 
of opportunistic infection. Infections such as tuberculosis cause 
a decrease in food intake because of changes in the secretion of 
cytokines, glucocorticoids, peptides, and insulin and insulin-like 
growth factors.3,4 Malnutrition is also exacerbated by decreases 
in both nutrient absorption and efficiency of utilisation owing to a 
damaged intestinal lining and increased energy expenditure during 
HIV-related illnesses.3,5
A combination of adequate nutrition and medical treatment for HIV/
AIDS and tuberculosis is crucial in improving the nutritional status, 
and lowering the risk, of co-infections in infected individuals. It is also 
vital in the management of opportunistic infections, and is believed 
to delay disease progression, thus improving quality of life and 
survival.6 However, meeting the increased nutritional requirements of 
HIV-infected individuals can be challenging.7 People living with HIV/
Abstract
Objectives: The objective of the study was to determine consumer acceptance and perceptions of a ready-to-use supplementary food (RUSF) 
by subjects treated for human immunodeficiency virus (HIV) and HIV and tuberculosis (co-infected subjects).
Design: A cross-sectional study was conducted.
Subjects: One hundred and thirty-nine stable HIV-treated and HIV and tuberculosis (co-infected)-treated patients participated in the study. 
Sixty-eight healthy subjects served as the control group.
Setting: The setting was Northdale Hospital and Grey’s Hospital in Pietermaritzburg, KwaZulu-Natal. 
Outcome measures: Acceptance of the RUSF was assessed using a five-point facial hedonic scale by stable HIV-treated and HIV and 
tuberculosis (co-infected)-treated patients (n = 139) from Northdale Hospital and Grey’s Hospital in Pietermaritzburg, KwaZulu-Natal. 
Perceptions of the RUSF were determined through focus group discussions in which HIV-treated and HIV and tuberculosis (co-infected)-treated 
patients (n = 43) participated.
Results: The overall acceptance of the RUSF was significantly associated with the health status of the subjects (p-value < 0.05). Overall, the 
product was liked by more than 90% of the HIV-treated and HIV and tuberculosis (co-infected)-treated individuals compared to 85% of the 
control group. More than 90% of the HIV-treated and HIV and tuberculosis (co-infected)-treated individuals liked the taste, compared to 87% 
of the control group. The colour and mouth feel were rated to be “good” by more than 80% of the HIV-treated and HIV and tuberculosis (co-
infected)-treated group, compared to approximately 70% of the healthy group. Focus group discussions revealed that the subjects perceived 
the mouth feel of the RUSF to be “rough”, and that as a health supplement, the RUSF should be provided free of charge, or at a reasonable 
cost, at public health centres.
Conclusion: The RUSF was found to be highly acceptable to stable HIV-treated and HIV and tuberculosis (co-infected)-treated subjects, 
although concern was raised about the mouth feel. 
 Peer reviewed. (Submitted: 2013-07-02. Accepted: 2013-10-26.) © SAJCN S Afr J Clin Nutr 2014;27(1):31-37
32
Original Research: Acceptance of a ready-to-use supplementary food
2014;27(1)S Afr J Clin Nutr
Original Research: Acceptance of a ready-to-use supplementary food
AIDS often fail to acquire nutritious foods. In addition to metabolic 
changes, the pharmaceutical agents used to treat these conditions 
also manifest in side-effects that can directly affect food intake, as 
well as compliance with drug treatment.8,9 
Various forms of ready-to-use supplementary foods (RUSFs) were 
introduced to prevent and alleviate malnutrition globally.10-12 In 2004, 
a RUSF was developed for use by the Gift of the Givers Foundation, 
a South African nongovernmental humanitarian and disaster relief 
organisation. The RUSF is produced in Malawi13 from peanuts and 
soya paste, with added micronutrients, which may affect the sensory 
properties of the product. Sensory properties play a vital role in the 
eating and purchasing behaviour of consumers.14 Any supplement 
must first be acceptable to the target consumers in order for it to be 
consumed.15 It is also well accepted that food and beverages should 
not be produced, distributed or marketed without first assessing 
consumer acceptance thereof.14 Yet, no data exist on the consumer 
acceptance of this RUSF. This product was developed approximately 
a decade ago at the height of the local HIV pandemic when nutrition 
intervention was the primary method of treatment, and just before 
implementation of the first South African National Comprehensive 
HIV and AIDS Treatment Programme. The prevention of AIDS-related 
weight loss and resulting malnutrition was the primary focus of 
most clinical practitioners, who had to deal with large numbers of 
dying patients. The development of the product was driven by need, 
and based on its demand, arrived on the market without having the 
necessary scientific therapeutic backing. Its use was based purely 
on anecdotal evidence. Yet, even in the era of anti-retroviral therapy 
(ART), nutrition intervention remains important.16
A number of acute and chronic complications associated with ART 
relate to nutrition, or require nutrition management in some way.17 
Complications mainly occur because of acute interactions of the drug 
regimens with some nutrients, and chronic metabolic disturbances 
that result over time. Acute side-effects, mostly gastrointestinal, 
such as nausea, diarrhoea and bloating, in addition to taste 
disturbances, appetite suppression, the inability to eat secondary to 
complicated medical regimens, or fatigue, as well as the presence of 
opportunistic infections, can impair food intake. It is also not unusual 
for ART agents in general,18,19 and didanosine in particular,20-22 to 
induce xerostomia (dry mouth syndrome and associated changes 
in taste perception) by an unknown mechanism. Xerostomia may 
be observed in up to one third of patients taking didanosine.23 Taste 
abnormalities are also common with the protease inhibitors, and 
oral and perioral paresthesia can be a disturbing adverse effect. 
Ritonavir, in particular, can give rise to circumoral paresthesia in over 
25% of patients.18,24 Therefore, in this study, the sensory acceptance 
and perceptions of this RUSF by subjects treated for HIV, AIDS and 
tuberculosis were assessed.  
Method
Study type and objectives 
A cross-sectional study was conducted to determine the 
acceptance and perceptions of a RUSF by stable HIV-treated and 
HIV and tuberculosis (co-infected)-treated patients through sensory 
evaluation and focus group discussions. 
Ready-to-use supplementary food samples
Samples of the RUSF were provided by the Gift of the Givers 
Foundation, which purchases and distributes the product as 
part of its humanitarian and disaster relief efforts. The nutritional 
composition analysis data (results not shown) were consistent with 
the nutritional information on the product label.
Study population and sample size
Sensory evaluation
Healthy subjects (control group) were recruited from staff and 
students of the University of KwaZulu-Natal, Pietermaritzburg, 
through verbal invitation, written letters and advertisements. 
A control group that was free of HIV and HIV and tuberculosis (co-
infection) were used to determine whether or not the health condition 
[HIV, and HIV and TB (co-infection)] affected the sensory acceptance 
of the product by comparison. The experimental group consisted 
of two patient types: HIV patients, and HIV and tuberculosis (co-
infected) patients. These subjects were also a convenience sample, 
but recruited from patients who attended the hospital clinics.  The 
co-infected panellists were recruited from Northdale Hospital 
because more patient consultations took place there per day than at 
Grey’s Hospital. HIV-only patients were recruited from both Northdale 
Hospital and Grey’s Hospital. 
Subjects were recruited to participate in the sensory evaluation in 
the same way as the healthy subjects. The sample size for each 
group had to include 50 or more subjects, in keeping with the 
accepted sample sizes for consumer sensory evaluation.14 In this 
study, eligible subjects who responded to the invitation participated. 
The inclusion criteria for both the experimental group and control 
group were: 
•	 Being between the ages of 18 to 55 years.
•	 Should not have smoked 30 minutes before participating in the 
study.
•	 Should not have a nut allergy.  
In addition, clinic or hospital cards were used to confirm that HIV-
only patients were receiving antiretroviral (ARV) drugs. The HIV 
and tuberculosis (co-infected) patients had to produce the Directly 
Observed Treatment, Short-course card as confirmation that they 
were receiving tuberculosis treatment. As outpatients, none of them 
suffered from serious uncontrolled complications that required 
additional medical intervention. By contrast, the control group had 
to be healthy, and not taking medication or treatment for any chronic 
illnesses, including HIV and tuberculosis.  
Focus groups
The focus group discussion participants were sampled from the HIV-
treated and HIV and tuberculosis (co-infected)-treated subjects who 
participated in the sensory evaluation. Subjects who were willing to 
participate in the focus group discussions were included.
Method of data collection
Sensory evaluation 
The sensory evaluation sessions were held in a room with separate, 
isolated booths set up for each panellist. Sensory evaluation of the 
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control group was conducted in a food-processing laboratory at the 
University of KwaZulu-Natal, while evaluation of the HIV-treated and 
HIV and tuberculosis (co-infected)-treated subjects was performed 
at the hospital clinics. 
Each panellist received a spoon and a small polystyrene cup 
containing 5 g of the RUSF.  The sample was blind-labelled with a 
three-digit code obtained from a table of random numbers.25  Prior to 
each session, the sensory attributes of taste, smell, colour, mouth feel 
and overall acceptance were explained to the panellists. An equally 
spaced five-point facial hedonic scale with ratings (5 = “super 
good”, 4 = “good”, 3 = “maybe good or maybe poor”, 2 = “poor” 
and 1 = “super poor”) was used to rate the sample. This rating scale 
is recommended for illiterate persons and children.14 Longer hedonic 
scales, e.g. 7 or 9 ratings, tend to confuse subjects with lower 
literacy levels, while rating scales that are shorter than the five-point 
scale tend to cause end-point avoidance.14 Background information 
indicated that some of the study subjects had low literacy levels. The 
sensory evaluation forms were developed in English and translated 
into isiZulu as the majority of the subjects were isiZulu speakers. 
Each sensory attribute was described on the form with an 
accompanying facial hedonic scale. The participants were asked to 
rate the acceptance of each attribute by marking the appropriate 
response on the facial hedonic scale. The forms were tested for 
content and face validity by an expert panel (n = 7) comprising 
academics working in the field of food science and nutrition. The 
ratings of the hedonic scale were verbally explained to the panellists 
in isiZulu at the sensory evaluation sessions. The researchers asked 
the panellists if they understood the ratings, which they confirmed 
they did. 
Focus groups
The aim was to determine if the consumers had perceptions of the 
RUSF which could affect its acceptance. The focus group discussions 
where held, separately, with subjects of the two patient types: the 
HIV-only treatment group and the HIV and tuberculosis (co-infected) 
treatment group. The HIV-only subjects were divided into four 
subgroups, each with 6-8 subjects. Three subgroups of the HIV-only 
subjects consisted of subjects who had never seen and consumed 
the RUSF before the study. The fourth subgroup consisted of subjects 
who had previously consumed the product. This decision was taken 
to reduce the possible influence of those who were familiar with the 
product on those who were not. 
The HIV and tuberculosis (co-infected)-treated subjects were divided 
into two subgroups. This was owing to the small number of co-
infected patients who were treated at the hospital clinic daily. One 
of the subgroups of the HIV and tuberculosis (co-infected)-treated 
group comprised subjects who were not familiar with the RUSF, and 
the other subgroup consisted of subjects who were. 
The focus group discussions were conducted in a staff room at 
Northdale Hospital by a trained facilitator in isiZulu to ensure that 
participants participated and fully understood the questions. The 
sessions were recorded using a digital voice recorder, and the 
recordings were translated into English by an isiZulu-speaking 
person. The English translations were then compared with the isiZulu 
recordings and checked for accuracy by another isiZulu-speaking 
person. Healthy consumers were not included in the focus group 
discussions because the RUSF was developed for malnourished 
individuals.
Ethical approval
Ethical approval to conduct the study was obtained from the University 
of KwaZulu-Natal, Humanities and Social Sciences Research Ethics 
Committee (reference number HSS/0374/011M). Approval was 
also obtained from Northdale Hospital and Grey’s Hospital. Written 
consent to participate in the study was obtained from subjects. The 
consent form was translated from English to isiZulu, and its contents 
explained verbally in isiZulu to recruited subjects. The identities of 
the subjects were kept confidential.
Statistical analysis
Data from the sensory evaluation questionnaires were analysed 
using the Statistical Package for the Social Sciences® version 18 
(SPSS Inc, Chicago, USA). Sensory evaluation data were analysed 
using descriptive statistics analysis techniques. A p-value of less than 
0.05 derived from the chi-square test was taken to be significant. 
Results
Sample sizes, description and demographic characteristics
Two hundred and seven consumers aged 18-55 years participated in 
the sensory evaluation (Table I). 
They were grouped according to their health status as follows: 
•	 The HIV-treated group (n = 88).
•	 The HIV and tuberculosis (co-infected)-treated group (n = 51).
•	 The healthy or control group (n = 68).  
The majority of consumers (n = 77) were aged 26-35 years. There 
was a very high proportion of black participants (92%), compared to 
other races. Seventy-one per cent of the participants were female. 
The demographic characteristics of the control group, and the HIV-
treated, and HIV and tuberculosis (co-infected)-treated groups, 
were similar in terms of age and race (Table I). Forty-three subjects 
participated in the focus group discussions. Thirty-two subjects 
represented the HIV-treated group and 11 subjects the HIV and 
tuberculosis (co-infected)-treated group. Of the total sample, 77% 
(n = 33) were female. The sample comprised mainly black Africans 
(95%, n = 41). Some coloureds (5%, n = 2) participated.
Consumer sensory acceptance of the ready-to-use 
supplementary food
Very few subjects from both groups rated the RUSF as “super 
good” or “super bad”. Therefore, a decision was taken to reduce 
the ratings to three categories of “poor”, “neutral” and “good” for 
simplified and meaningful interpretation of the results. A score 
≥ 4 signified that the sensory attribute was good, 3 neutral, and ≤ 2 
poor. In terms of overall acceptance of the RUSF (Table II), more than 
90% of the consumers in the HIV-treated and HIV and tuberculosis 
(co-infected)-treated group, respectively, perceived the product to 
be “good”, compared to 85% of consumers from the healthy group 
who provided the same rating for overall acceptance of the product. 
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HIV-treated group  
(n = 88)





n % n % n % n %
Age
18-25 years 43 21 10 11 5 10 28 41
26-35 years 77 37 35 40 20 39 22 32
36-45 years 51 25 27 31 13 25 11 16
46 years and older 36 17 16 18 13 25 7 10
Gender 
Female 147 71 75 85 23 45 44 65
Male 60 29 13 15 28 55 24 35
Race
Black 190 92 88 100 49 96 53 78
Coloured 3 1 0 0 1 2 2 3
Indian 8 4 0 0 1 2 7 10
White 6 2 0 0 0 0 6 9
HIV: human immunodeficiency virus
Table II:  Consumer acceptance of the ready-to-use supplementary food across health status, age and gender
Sensory 
attributes































Poor 7 (10.3) 4 (4.5) 1 (2) 2 (4.7) 6 (7.8) 2 (3.9) 2 (5.6) 11 (7.5) 1 (1.7)
Neutral 3 (4.4) 4 (4.5) 1 (2) 2 (4.7) 4 (5.2) 1 (2) 1 (2.8) 5 (3.4) 3 (5)
Good 58 (85.3) 80 (90.9) 49 (96.1) 39 (90.7) 67 (87) 48 (94.1) 33 (91.7) 131 (89.1) 56 (93.3)
Taste 0.02 0.27 0.28
Poor 7 (10.3) 5 (5.7) 1 (2) 3 (7) 6 (7.8) 1 (2) 3 (8.3) 11 (7.5) 2 (3.3)
Neutral 2 (2.9) 3 (3.4) 4 (7.8) 2 (4.7) 3 (3.9) 4 (7.8) 0 (0) 8 (5.4) 1 (1.7)
Good 59 (86.8) 80 (90.9) 46 (90.2) 38 (88.4) 68 (88.3) 46 (90.2) 33 (91.7) 128 (87.1) 57 (95)
Smell 0.01 0.31 0.70
Poor 1 (1.5) 7 (8) 0 (0) 2 (4.7) 1 (1.3) 2 (3.9) 3 (8.3) 6 (4.1) 2 (3.3)
Neutral 11 (16.2) 4 (4.5) 6 (11.8) 8 (18.6) 9 (11.7) 2 (3.9) 2 (5.6) 16 (10.9) 5 (8.3)
Good 56 (82.4) 77 (87.5) 45 (88.2) 33 (76.7) 67 (87) 47 (92.2) 31(86.1) 125 (85) 53 (88.3)
Colour 0.00 0.05 0.34
Poor 9 (13.2) 9 (10.2) 3 (5.9) 7 (16.3) 8 (10.4) 3 (5.9) 3 (8.3) 19 (12.9) 2 (3.3)
Neutral 13 (19.1) 3 (3.4) 4 (7.8) 9 (20.9) 6 (7.8) 2 (3.9) 3 (8.3) 14 (9.5) 6 (10)
Good 46 (67.6) 76 (86.4) 44 (86.3) 27 (62.8) 63 (81.8) 46 (90.2) 30 (83.3) 114 (77.6) 52 (86.7)
Mouth feel 0.06 0.00 0.46
Poor 11 (16.2) 10 (11.4) 4 (7.8) 6 (14) 11 (14.3) 3 (5.9) 5 (13.9) 21 (14.3) 4 (6.7)
Neutral 9 (13.2) 2 (2.3) 4 (7.8) 10 (23.3) 1 (1.3) 2 (3.9) 2 (5.6) 11 (7.5) 4 (6.7)
Good 48 (70.6) 76 (86.4) 43 (84.3) 27 (62.8) 65 (84.4) 46 (90.2) 29 (80.6) 115 (78.2) 52 (86.7)
HIV: human immunodeficiency virus
*: p-values generated using the chi-square test
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Similarly, more consumers in the HIV-treated and HIV and tuberculosis 
(co-infected)-treated groups rated the taste, smell, colour and mouth 
feel of the product to be “good” relative to consumers in the healthy 
group. The acceptance of the RUSF was significantly associated with 
the health status of the consumer (p-value < 0.05). There was a 
significant association between the colour and mouth feel acceptance 
of the product and the age of the consumer (p-value < 0.05), while 
smell, taste and overall acceptance were not associated with the 
consumer’s age (p-value > 0.05). Approximately 63% of the younger 
consumers, aged 18-25 years, rated the colour and mouth feel of the 
product to be “good”, compared to more than 80% of consumers in 
the older age group, who rated the two sensory attributes to be the 
same. Acceptance of the product was not associated with the gender 
of the consumer (p-value > 0.05).
Focus group discussions 
Table III outlines responses to open-ended questions asked during 
the focus group discussions. The HIV-treated subjects liked the smell 
and colour of the RUSF, and associated both properties with peanut 
butter. However, some of these subjects disliked its mouth feel. 
The HIV and tuberculosis (co-infected)-treated group also liked the 
taste of the RUSF, and associated it with peanut butter and porridge 
received from the clinic. These subjects also reported that the smell 
and colour of the product was nutty, and like that of peanut butter. 
The HIV and tuberculosis (co-infected)-treated group, in particular, 
seemed to be concerned about the mouth feel of the product. It was 
suggested that the RUSF should be changed from a rough to a smooth 
product. Both groups agreed that they would purchase it. Subjects 
from the HIV and tuberculosis (co-infected)-treated group expressed 
greater willingness to purchase it, but recommended that it should 
be affordable. The HIV-treated subjects were of the opinion that the 
product should be provided free of charge at the public health centre 
visited. The HIV-treated subjects believed that the product’s price 
should range from R5-R35 per 500 g, while the HIV and tuberculosis 
(co-infected)-treated group suggested that it should be R13-R80 
per 500 g. Consumers from the HIV and tuberculosis (co-infected)-
treated group were willing to pay more for the RUSF as they had 
used it previously, and were familiar with the nutritional qualities 
therein. Consumers from both groups based the suggested price for 
the RUSF on the amount of money spent on peanut butter.
Discussion
Sensory evaluation
The high acceptance of the RUSF by consumers treated for HIV, 
and HIV and TB co-infection, and without serious uncontrolled 
complications, implies that the ARV and tuberculosis treatment did 
not negatively affect their perception of the sensory properties of 
the product. 
Physiological changes, such as oesophageal thrush, lack of appetite, 
nausea and vomiting, are known to have a negative effect on 
the acceptance of food.27 This was not encountered in the RUSF 
consumer acceptance findings as most participants in the study 
were at the recovery stage of HIV/AIDS, and didn’t have severe 
symptoms of the infection, especially in their mouths. 
The RUSF consumer acceptance finding in this study is in agreement 
with another one that was conducted on the acceptance of a RUSF in 
Kenya by malnourished, adult HIV-positive patients on ART.28 However, 
in yet another study conducted in Kenya on a peanut-based RUSF, 
malnourished adult AIDS patients on ART reported the supplement to 
be unacceptably salty or too sweet.27 High acceptance of the taste 
and smell of the product by healthy consumers in this study may be 
owing to the unique peanut butter flavour found in peanut-containing 
foods.29 The level of acceptance of the taste, smell, colour and 
mouth feel of the product decreased in younger consumers (aged 
18-25 years), probably because of their higher sensory thresholds 
(relative to the older consumers). A decrease in sensitivity to sensory 
properties with age has been reported previously.30,31 The lower 
scores on mouth feel relative to the scores for the other sensory 
attributes are in line with the focus group discussion findings which 
indicated that the mouth feel of the product should be changed to a 
smoother one. 
Focus group discussions
The subjects perceived the product to have a “rough” mouth feel. The 
mouth feel was considered to be unacceptable by some. The mouth 
feel was rated by the majority of the subjects as “good” in sensory 
acceptance testing, although during the focus group discussions, 
subjects indicated that they would prefer a smooth product. The 
subjects seemed to base their perception and expectation of the 
RUSF mouth feel on the health status of possible users. It was 
suggested that illness would negatively affect acceptance of the 
RUSF. The study subjects also perceived the product to be a health 
supplement. It became evident that viewing it as such, rather than 
as a food, would affect its provision, regardless of its nutritional 
attributes. Health supplements are usually provided free of charge 
at public health centres. Thus, subjects expected this in respect of 
this RUSF, or for the product to be sold at a reasonable cost. It was 
also suggested that if the RUSF was issued free of charge as a health 
supplement, the recipient might be stigmatised for having an illness.
Conclusion
The RUSF was highly acceptable to the HIV-treated and HIV and 
tuberculosis (co-infected)-treated consumers in this study, who were 
not suffering from serious uncontrolled complications at the time 
it was conducted. These consumers perceived the product to be a 
health supplement. The HIV-treated subjects, in particular, expected 
it to be provided free of charge at health centres. A change in the 
mouth feel of the RUSF from rough, crunchy and oily, to relatively 
smooth and less oily, should be considered by the manufacturer of 
the supplement. Based on the findings of this study, implementing 
this change would improve its consumer acceptance, especially by 
HIV-infected individuals in a more advanced disease state and in 
therapeutic need of a RUSF, but without symptoms of the infection, 
especially of the mouth, which can negatively affect acceptance of 
the product. If the product is reformulated and its properties changed, 
e.g. the texture, it should be re-evaluated by similar subjects.
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